Literature DB >> 34714485

Anticancer activity of N-heteroaryl acetic acid salts against breast cancer; in silico and in vitro investigation.

Samaneh Zolghadri1, Ali Ghanbariasad2, Fatemeh Fallahian1, Mahdie Rahban3, Mahsa Kalavani1, Enayatollah Bahman Jahromi1, Azizeh Asadzadeh4, Maliheh Hajiani5.   

Abstract

BACKGROUND: The present research was performed to assess N-heteroaryl acetic acid salts' anticancer activity against the breast cancer cell in order to introduce new inhibitory agents for histone deacetylase. METHODS AND
RESULTS: A molecular docking simulation was performed to design the rational novel compounds. Afterward, the best compounds were selected for synthesis. The cytotoxic effects and mechanism of action have been studied via (Methyl Thiazol-Tetrazolium) MTT assay. Flow cytometry and gene expression analyses were performed to introduce an effective acetic acid derivative as an anticancer agent. Molecular docking simulations demonstrated that all compounds have the best interaction with histone deacetylase. The fold changes of Bcl-2, Bak, Bim, Caspase-3, and Caspase-8 gene expressions were investigated and compared with reference gene using real-time PCR. The cytotoxic studies showed the best anticancer activity of 4-benzyl-1-(carboxymethyl) pyridinium bromide (compound 2) with a low IC50 value (32 µM, p < 0.05). Also, the best anti HDAC activity was obtained for compound 2 with IC50 value of 1.1 µM. Furthermore, this compound showed a high percentage of apoptosis among all tested compounds after 72 h incubation which was associated with the significant increase in mRNA level of Bim, Bax, Bak, Caspase-3, and Caspase-8 and the considerable decrease in Bcl2 gene expression.
CONCLUSION: These results suggest that compound 2 with the benzyl ring could be an effective anticancer compound for further investigation in breast cancer treatment.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Anticancer; Apoptosis; Breast cancer; Flow cytometry; HDAC inhibitor; Real-time PCR

Mesh:

Substances:

Year:  2021        PMID: 34714485     DOI: 10.1007/s11033-021-06881-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  1 in total

Review 1.  Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?

Authors:  Christos Damaskos; Ioannis Tomos; Nikolaos Garmpis; Anna Karakatsani; Dimitrios Dimitroulis; Anna Garmpi; Eleftherios Spartalis; Christos F Kampolis; Eleni Tsagkari; Angeliki A Loukeri; Georgios-Antonios Margonis; Michael Spartalis; Nikolaos Andreatos; Dimitrios Schizas; Stefania Kokkineli; Efstathios A Antoniou; Afroditi Nonni; Gerasimos Tsourouflis; Konstantinos Markatos; Konstantinos Kontzoglou; Alkiviadis Kostakis; Periklis Tomos
Journal:  Anticancer Res       Date:  2018-01       Impact factor: 2.480

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.